Patients with excited delirium often are administered ketamine by EMS before arriving at the hospital. Many of them are intoxicated or are using illicit substances, which may alter the properties of ketamine.
Used for the treatment of depression that does not respond to standard antidepressant medications, the anesthesia drug ketamine – and the related drug esketamine, recently approved for depression treatment – has no important adverse effects on memory, attention, or other cognitive processes, concludes a systematic review of medical research in the September/October issue of Harvard Review of Psychiatry. The journal is published in the Lippincott portfolio by Wolters Kluwer.
The discovery that the anaesthetic ketamine can help people with severe depression has raised hopes of finding new treatment options for the disease.
A new study at the University of Chicago Medicine and Washington University found that a single inhalation session with 25% nitrous oxide gas was nearly as effective as 50% nitrous oxide at rapidly relieving symptoms of treatment-resistant depression, with fewer adverse side effects.
Study offers a key finding in the development of a promising treatment
In a new study, published in Current Biology, researchers from the University of California, Irvine School of Medicine reveal how subanesthetic ketamine, which is used for pain management and as an antidepressant in humans, is effective in treating adult amblyopia, a brain disorder commonly known as “lazy eye.”
The American Society of Anesthesiologists firmly opposes the use of ketamine or any other sedative/hypnotic agent to chemically incapacitate someone for a law enforcement purpose and not for a legitimate medical reason. Ketamine is a potent analgesic, sedative and general anesthetic agent which can elevate blood pressure and heart rate, and can lead to confusion, agitation, delirium, and hallucinations. These effects can end in death when administered in a non-health care setting without appropriately trained medical personnel and necessary equipment.
Researchers at the Seaver Autism Center for Research and Treatment at Mount Sinai have started recruiting participants for a new clinical trial to evaluate the safety, tolerability, and efficacy of a low dose of ketamine in children diagnosed with ADNP syndrome (also known as Helsmoortel-VanDerAa syndrome), a rare neurodevelopmental disorder caused by mutations in the activity dependent neuroprotective protein (ADNP) gene.
Researchers at Beaumont Health have begun enrolling patients in a new clinical study aimed at treating COVID-19 patients with two common drugs.
Nearly 37 percent of electronic dance music (EDM) party attendees test positive for ketamine use when samples of their hair are tested—despite only 14.6 percent disclosing that they have used the drug in the past year.
Researchers at Thomas Jefferson University and the University of Virginia retrospectively analyzed patient records see if side effects increased after repeated infusions. They actually found a couple of benefits.